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Abstract
Tuberculosis (TB) is one of the top 10 causes of death worldwide. TB has further been 
exacerbated by the HIV/AIDS pandemic, the emergence of multidrug-resistant (MDR) TB 
and extensively drug-resistant TB. In 2015, approximately 1.4 million people and 400,000 
who were HIV-negative and HIV-positive, respectively, died of TB. There were 10.4 mil-
lion new cases with active TB of which 2.4 million were HIV co-infected and 480,000 new 
cases with MDR-TB. Conclusions: TB is a multifaceted disease and there is no one size 
fits all test for its diagnosis. In the 22 high TB burden countries (HTBBC), which har-
bour 80% of global TB, sputum smear microscopy with its low detection rate remains the 
most commonly used diagnostic test for pulmonary TB. Culture, the gold standard for 
TB diagnosis, the molecular-based tests for both rapid diagnosis and detection of drug 
resistant TB because of the requirement for specialized laboratories and trained person-
nel as well as other costs is not routinely used in most HTBBC. An accurate, affordable, 
point-of-care TB test, with no requirement for electricity, specialized laboratory, easily 
performed by healthcare personnel is what is urgently needed for TB control.
Keywords: sputum smear microscopy, TB-LAMP, LAM-LF, culture, MTB/RIF assay, 
line-probe assays
1. Introduction
Tuberculosis (TB), one of the top 10 major causes of death globally is a major public health 
priority. Of the 10.4 million people diagnosed with active TB in 2015, the  majority occurred in 
people living in low- and middle-income countries. The TB epidemic has further been exac-
erbated by the HIV/AIDS pandemic and the emergence of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) TB. Of the estimated 1.8 million people who died in 2015, 1.4 
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million were HIV negative and 400,000 were HIV positive. In the same period, 480,000 cases of 
MDR TB and a further 100,000 that were estimated to be rifampicin-resistant [1].
TB mainly affects the lungs (pulmonary TB), however, it can affects other parts of the body 
such as the spine or brain (extrapulmonary TB). Although TB is a preventable and curable 
disease, failure to detect the disease early is one of the major bottlenecks to TB control. TB 
diagnostic tests with low sensitivity that were developed more than a century ago are still 
in use today. The detection case rates in the 22 high burden countries which harbor 80% of 
global TB burden is low (~50%) and even lower among the HIV-infected. [2]. From the 10.4 
million people who developed TB in 2015, 4.3 million cases were not diagnosed or notified 
and only one quarter of MDR TB cases (132,000) were detected and reported. The reasons 
for the low detection and underreporting of TB are multifactorial and include limited or 
delayed access to appropriate diagnosis and care, large private sectors not reporting cases, 
and the lack of access to appropriate diagnostic tools due to geographic and/or financial 
barriers [3–5].
The WHO Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) provides 
objective, ongoing technical and strategic advice to the WHO regarding TB diagnosis, care 
and control (http://www.who.int/tb/advisory_bodies/stag/en/index.html). The group which is 
comprised of 22 experts representing ministries of health, national TB control programs, aca-
demic and research institutions, civil society organizations, communities and patients affected 
by TB, and professional associations provides the WHO Director General with independent 
evaluations of the strategic, scientific, and technical aspects of WHO’s area of work in TB. The 
group also reviews progress and challenges in TB-related core functions such as policies, strat-
egies, and standards and make recommendations on committees and working groups. The 
STAG-TB reviews policy drafts and supporting documentation and may endorse the policy 
recommendation with or without revisions, request additional information and re-review the 
evidence in subsequent years, or reject the recommendation.
Below, we describe the WHO recommended TB diagnostic tools, the advantages and disad-
vantages as well as challenges in the implementation of the tools.
2. World Health Organization (WHO) approved TB diagnostic tools
2.1. Sputum smear microscopy for the diagnosis of pulmonary TB
Direct microscopic examination of sputum for acid-fast bacilli (AFB), the sputum smear micros-
copy (SSM) remains the most commonly used diagnostic test for pulmonary TB particularly in 
countries with a high rate of TB infection [6].
The test is conducted by placing a thin layer of the sputum (smear) on a glass slide. A series 
of special stains are then applied to the smear, and the stained slide is examined under a 
microscope for signs of the TB bacteria [7]. It is a simple inexpensive test which does not 
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require sophisticated laboratory infrastructure or extensive training of laboratory personnel 
and the results are available within hours. Although its sensitivity is only about 50–60%, 
its high specificity (99–100%) ensures that only those who are positive receive the anti-TB 
treatment [8]. The detection rate is even lower in countries with a high prevalence of both 
pulmonary TB and HIV infection, as many patients with HIV and TB co-infection have very 
low levels of TB bacteria and are unable to produce good quality sputum leading to false 
negative results [9].
SSM has other limitations in addition to its low sensitivity. False positive results may occur in 
individuals that have been infected with NTB. False negative results particularly happen with 
children, older people and HIV-infected patients. Furthermore, SSM cannot be used to diag-
nose extrapulmonary TB. Many HIV-infected patients tend to have high rates of extrapul-
monary TB compared to HIV negative individuals which probably contributes to the lower 
sensitivity of FM in this group of patients [9].
In the earlier years, a conventional light microscope for examining the AFB Ziehl-Neelsen 
(ZN) stains was recommended for SSM in low-income and middle-income countries where 
most of the world’s TB cases occur [10, 11]. In high-income countries, AFB auramine O or 
auramine-rhodamine stains are examined by fluorescence microscopy (FM) which has a 
higher sensitivity than conventional ZN light microscopy. In these countries, FM is the most 
commonly used method for diagnosis of pulmonary TB [12].
In FM, the smear is illuminated with a quartz halogen or high pressure mercury vapor lamp, 
allowing a much larger area of the smear to be seen and resulting in more rapid examination 
of the specimen. The major advantage of FM is that it uses a lower power objective lens com-
pared to conventional microscopy thus reducing the time of assessing the same area of a slide 
[13]. The major disadvantage of using FM is the expensive mercury vapor lamp which lasts 
a very short time. The lamp also takes a while to warm up, burn high amounts of electricity, 
and electricity supply problems can significantly shorten its life span [14]. The use of light 
emitting diodes (LEDs) which switch on extremely quickly, have an extremely long life, and 
do not explode can address some of these problems [14].
In 2006, a systematic review of 45 studies comparing conventional SSM with FM reported 
that FM has a higher sensitivity than the standard light microscopy but similar specificity 
with standard light microscopy [15]. In HIV positive patients, there was insufficient data to 
determine the value of FM.
Following a systematic review in September 2009, of a meta-analysis of published and unpub-
lished data, the WHO assessed the evidence for the efficacy of LED microscopy. Subsequently 
in 2011 the WHO issued a policy statement recommending that conventional FM should be 
replaced by LED microscopy [16].
The advantages of LED microscopes are: they are less expensive, require less power and are 
able to run on batteries, the bulbs have a very long half-life and do not pose the risk of releas-
ing potentially toxic products if broken.
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In 2011, the WHO revised its earlier recommendations of using three sputum specimens col-
lected on different days to same day microscopy using two sputum specimens collected at 
the same time, on the same day based on a systematic review of 37 eligible studies [17, 18]. 
However, the WHO recommended its use only in settings with a well-established laboratory 
network and a fully functional external quality assurance program for SSM including on-site 
evaluation and follow-up training for problem laboratories.
The revised recommendation has reduced the number of patient visits to the clinic, leading 
to a reduction in the numbers of TB positive cases that are lost to follow up, reduced labora-
tory workload as well as decreased time for diagnosis and initiation of anti-TB treatment with 
non-significant decrease in diagnostic yield [19].
2.2. Loop-mediated isothermal amplification (TB-LAMP) for diagnosis of 
pulmonary TB
A commercial molecular assay Loopamp MTBC Detection Kit was developed by Eiken 
Chemical Company Ltd. (Tokyo, Japan) for the detection of MTBC (TB-LAMP) [20].
The assay is based on loop-mediated isothermal amplification. It is a manual assay that 
requires less than 1 h to perform and the result can be read with the naked eye under ultra 
violet (UV) light. The assay consists of three steps, sample preparation (10–20 min), ampli-
fication (40 min), and visual detection of fluorescence light from the reaction tube using UV 
light (0.5–1 min) (Figure 1). Sputum is added to a heating tube containing the extraction 
solution which is then mixed by inverting, the heating tube is placed into the heating block 
to lyse and inactivate mycobacteria. The heating tube is then removed from the heating 
block and allowed to cool. The heating tube is then attached to an adsorbent tube and mixed 
by shaking until all the powder has been completely mixed with the solution. An injection 
cap is placed onto the adsorbent tube and screwed tightly to pierce the seal. The nozzle is 
then inserted into a reaction tube and drops of solution are transferred to the reaction tube. 
Amplification is carried out by loading the reaction tubes into the heating block and the 
reaction started. The amplification is stopped automatically after 40 min. For visual detec-
tion of fluorescent light, the reaction tubes are transferred into a fluorescence detector and 
the results recorded [21, 22].
The TB-LAMP assay has several features that makes it attractive as a diagnostics platform 
for resource-poor settings: it is fast (40 min), isothermal (requiring only a heat block), robust 
to inhibitors and reaction conditions that usually adversely affect polymerase chain reaction 
(PCR) methods, and it generates a result that can be detected with the naked eye. The major 
disadvantage of TB-LAMP is that it cannot detect drug resistance and is therefore only suit-
able for testing of patients at low risk of MDR TB [22].
In January 2016, WHO Guideline Development Group (GDG) conducted a systematic 
review and meta-analysis of 24 studies conducted after 01 January 2012 to evaluate the use of 
TB-LAMP on sputum samples from adults with signs and symptoms consistent with pulmo-
nary TB that were conducted in settings with an intermediate or high burden of TB. Only 13 
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of the 24 studies met the eligibility criteria for inclusion in the systematic review. The pooled 
sensitivity of TB-LAMP was higher than that of SSM (78% vs. 63%). The pooled specificity of 
TB-LAMP was lower than that of SSM, 98% vs. 100%. In the HIV-infected patients, the pooled 
sensitivity of TB-LAMP was similar to that of SSM; 64% vs. 62% for SSM while specificity 
was the same, 99% for TB-LAMP and 99% for SSM. In the analysis of TB-LAMP for detec-
tion of pulmonary TB in adult patients who were SSM negative, TB-LAMP showed a 42% 
incremental yield [23].
In August 2016, WHO issued a policy recommendation on the TB-LAMP MTBC assay. 
TB-LAMP may be used as a replacement test for SSM to diagnose pulmonary TB in adults 
with signs and symptoms consistent with TB and TB-LAMP may be used as a follow-on test 
in adults with signs and symptoms consistent with pulmonary TB, especially when further 
testing of sputum smear-negative specimens is necessary. These recommendations apply to 
settings where conventional SSM can be performed, TB-LAMP should not replace the use 
of rapid molecular tests that detect TB and resistance to RIF, especially among populations 
at risk of MDR TB. Due to the limited evidence, it is unclear whether TB-LAMP has addi-
tional diagnostic value over SSM for testing persons living with HIV who have signs and 
symptoms consistent with TB. These recommendations are extrapolated to using TB-LAMP 
in children, based on the generalization of data from adults, while acknowledging the dif-
ficulties of collecting sputum specimens from children. TB-LAMP should not replace the 
Xpert MTB/RIF assay because the Xpert MTB/RIF assay can detect resistance to RIF whilst 
the former cannot [23].
Figure 1. Overview of Pure method (procedure for ultra-rapid extraction [21]).
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2.3. Gene Xpert MTB/RIF assay
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), is an automated semi-quantitative 
nested real-time PCR for the rapid detection of MTBC DNA and RIF resistance simultaneously, 
directly from unprocessed sputum within 2 h [24]. The assay has been extensively evaluated in 
various geographical settings and the diagnostic accuracy is good [25–31]. In a meta-analysis, 
the pooled sensitivity and pooled specificity of MTB/RIF were 88 and 95% respectively when 
used as an initial test for TB diagnosis. The pooled sensitivity was 80% in the HIV-infected 
patients. The pooled sensitivity and pooled specificity for detection of RIF resistance were 94 
and 98% respectively. Thus, it was concluded that the MTB/RIF assay is sensitive and specific 
as an initial test for diagnosis of TB, TB associated HIV and MDR TB [32].
The assay is very simple to run and can be performed by nurses with very little training [33]. 
Briefly, the assay is carried out by adding the sample reagent in a volume twice that of the 
untreated sputum and the mixture incubated for 15 min. Two millimeters of the processed spu-
tum is then transferred to the MTB/RIF assay catridge and then inserted into the Gene Xpert 
instrument, subsequent steps in the assay are completely automated and selfcontained. The 
advantages of the assay are its higher sensitivity when compared to SSM and shorter period 
(2 h) of obtaining the result when compared with culture which although it gives a definite diag-
nosis, it takes weeks. Furthermore the assay identifies RIF resistance within hours compared to 
the weeks taken to get any drug resistance result when using culture-based methods [34].
In 2011, WHO issued a policy statement recommending the use of the assay as a diagnostic tool 
for all people living with HIV who have signs and symptoms of TB, for people with unknown 
HIV status presenting with strong clinical evidence of HIV infection, for people who are seri-
ously ill and suspected of having TB regardless of HIV status and those at risk of MDR TB [35].
Although it has been muted as a new test which represents a major milestone for global TB 
diagnosis and care and new hope for the millions of people who are at the highest risk of TB 
and drug-resistant disease, it has some disadvantages [36]. The disadvantages include the 
short shelf life of the cartridges (only 18 months), very stable electricity supply is required, 
the instrument needs to be recalibrated annually, and the cost of the test and the temperature 
ceiling is critical [37]. To address some of these challenges, a new machine, the Xpert Omni 
which is intended for point of care (POC) testing for TB and RIF resistance, using the same 
cartridges as those used in the current Xpert machine is currently under development. It is 
expected that it will be smaller, lighter and less expensive than the current Xpert machine and 
will also come with a built-in 4 h battery [38].
A next generation cartridge called the GeneXpert Ultra (Ultra) was launched on 24 March 
2017, World TB Day [39]. Its sensitivity is higher than that of MTB/RIF with the greatest sensi-
tivity gains being recorded among SSM negative-culture positive patients, and HIV infected-
TB patients. It however, has a lower specificity than the MTB/RIF assay. The performance of 
the Ultra was assessed in 2016 in a multicentre non-inferiority study at 10 sites in 8 low- and 
middle-income countries. The performance of the Ultra assay was evaluated by the WHO 
Technical Experts Group in January 2016, which concluded that the Ultra test performed bet-
ter than the MTB/RIF assay in TB diagnosis of children, HIV-infected patients and patients 
with extra pulmonary TB, who more often than not are difficult to diagnose, however, there 
is a need for more research to be conducted to improve the specificity of the new test [40].
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The usefulness of the MTB/RIF has generated a lot of controversy. Some people consider the 
test to be extremely useful, as well as cost effective, and should be used in as many places as 
soon as possible while other people consider it not to be really suitable and practical at the 
present time for major use in low- and middle-income countries [41–43]. A clinical trial con-
ducted in four African countries in 2013 comparing the use of the Xpert to SSM concluded that 
using the Xpert meant that more patients had a same day diagnosis and same day treatment 
initiation, but the benefits did not translate into lower TB morbidity [33].
In spite the negatives concerning the usefulness of the MTB/RIF in so far as the outcomes of 
its use are concerned, its introduction since 2010 has revolutionized TB diagnostics as a POC 
test offering rapid TB diagnosis and simultaneous detection of RIF resistance. More than 23 
million Xpert machines had been procured in 130 countries and MDR TB diagnosis more than 
tripled by 2016 [44, 45].
2.4. Lipoarabinomannan urine strip test for TB diagnosis in HIV-infected patients
A POC lateral flow urine Lipoarabinomannan strip test (LF-LAM) developed by Alere 
Determine™ TB LAM Ag, Waltham, MA, USA for TB diagnosis is based on the detection of 
mycobacterial lipoarabinomannan (LAM) antigen in urine. Briefly 60 μL of freshly collected 
urine is applied to the test strip, incubated at room temperature for 25 min and the result 
recorded as negative if there was no presence of any band or recorded as positive and band 
graded using the manufacturer’s reference card with bands of graded intensity. The LF-LAM 
test has been evaluated for accuracy of TB diagnosis in HIV-infected patients in various geo-
graphical settings [46–53] albeit with widely varying sensitivity (13–93%) and specificity (87–
99%) [53]. The general consensus then was that the assay is most suitable for HIV-infected 
patients with CD4 counts < 200 cells/μL [54]. The variability in the performance characteristics 
of LF-LAM led the end users of the assay to request the WHO for guidance on the appropriate 
use of the assay.
In 2015, the WHO commissioned a systematic review of the use of LF-LAM assay for the 
diagnosis and screening of active TB in people living with HIV. The quantitative meta-analysis 
included 16 studies. Following the meta-analysis, the WHO recommended that the LF-LAM 
test may be used to assist in the diagnosis of TB in HIV positive adult in patients with signs and 
symptoms of TB (pulmonary and/or extra pulmonary) who have a CD4 cell count less than or 
equal to 100 cells/μL, or HIV positive patients who are seriously ill regardless of CD4 count 
or with unknown CD4 count [55]. This recommendation also applies to HIV positive children 
with signs and symptoms of TB (pulmonary and/or extra pulmonary) based on the generaliza-
tion of data from adults while acknowledging very limited data and concern regarding low 
specificity of the LF-LAM assay in children [55].
The advantages of LAM include use of urine which is easily and rapidly obtained even from 
very ill patients compared to sputum, it is an easy to use POC test which can also be per-
formed by trained nurses making it an ideal POC test. Its major disadvantage is that its use 
is restricted to a subgroup of HIV-infected TB suspects with low CD4+ T lymphocytes. The 
reasons for higher sensitivity and specificity in this group of patients are not fully understood. 
However, it is hypothesized that HIV patients with advanced immunosuppression may have 
a disseminated TB infection that is very difficult to rapidly diagnose with current tools. The 
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patients may have a higher bacterial load associated with widespread infection and, there-
fore, antigen load, the greater likelihood of genitourinary tract TB and greater glomerular 
permeability to allow increased antigen levels in urine [55].
2.5. Culture for TB diagnosis and drug resistance testing
Culture remains the gold standard for TB diagnosis and drug-resistant testing. Ideally cul-
ture examinations should be done on all diagnostic specimens, regardless of AFB smear or 
nucleic acid amplification results. Positive cultures for MTB confirm the diagnosis of TB dis-
ease; however, in the absence of a positive culture, particularly in RLCs, TB disease may also 
be diagnosed on the basis of clinical signs and symptoms alone. Two types of broth culture 
systems; liquid and solid media are commercially available. The commercial liquid culture 
systems and molecular line-probe assays have been endorsed by the WHO as gold standards 
for rapid detection of MDR TB [56, 57].
The drug resistance of clinical isolates as determined by conventional methods (e.g., broth-
based and agar proportion) is due to the presence of mutations in specific MTB genes [58]. 
These mutations often are single base pair changes in the DNA sequence of the bacteria. There 
are a variety of commercial assays and laboratory tests that can detect mutations associated 
with drug resistance. The assays are done on patient specimens or isolates from patient speci-
mens. The liquid based systems such as BACTEC, MGIT, VersaTREK and MBBACT allow 
detection of most mycobacterial growth in 4–14 days compared to 3–6 weeks for solid media 
[59]. However these tests require specialized laboratories and skills that are often unavailable 
in the regions, particularly RLS, where most cases of TB and MDR TB occur [59].
As an interim solution while capacity for genotypic or automated liquid culture and drug sen-
sitivity testing (DST) is being developed, in 2011, the WHO recommended non-commercial 
culture and DST methods for screening patients at risk for MDR TB namely (i) microscopic 
observation of drug susceptibility (MODS): a micro colony direct method in liquid culture, 
based on inoculation of specimens into drug-free and drug-containing media, followed by 
microscopic examination of early growth, (ii) colorimetric redox indicator (CRA): a direct or 
indirect method based on the ability of MTB to reduce nitrate, which is detected by a color 
reaction and (iii) nitrate reductase assay (NRI) methods: indirect methods based on the reduc-
tion of a colored indicator added to liquid culture medium on a microtitre plate after exposure 
of MTB strains to anti-TB drugs in vitro. These tests can only be used in reference laboratories 
and under strict laboratory protocols. The major disadvantage of these tests is that none can 
detect XDR TB and thus cannot replace the conventional culture and DST tests [60].
2.6. Molecular line-probe assays for diagnosis of TB and detection of drug 
resistance
The emergence of MDR TB and XDR TB threatens to reverse the gains that have been made in 
global control of TB. Rapid tests for detection of resistance to anti-TB treatment are urgently 
required for timeous and appropriate treatment which would lead to decreased morbidity 
and mortality as well as curbing new infections.
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The standard first line drugs for anti-TB treatment include RIF and INH. In patients with 
MDR TB, drugs belonging to fluoroquinolines (FLQ) and second line injectable drugs (SLID) 
are used. The FLQ drugs include ofloxacin, levoflacin, moxifloxacin and gatifloxacin while 
the SLID include kanamycin (KAN), amikacin (AMK) and capreomycin (CAP) [61]. Patients 
with XDR TB are resistant to RIF, INH, plus any FLQ and at least one of the three SLIDs thus 
making them resistant to both first line and second line anti-TB drugs [61].
Turnaround time (TAT) for DST results using the conventional solid based methods ranges 
from 8 to 12 weeks [62] thus contributing to new infections as those infected continue to trans-
mit drug-resistant TB. On 26 March 2007, the WHO recommended the use of liquid culture 
and DST in low- and medium-income countries [58] following evidence provided by the 
Foundation for Innovative New Diagnostics (FIND). Although the liquid media based tests 
such as BACTEC® (BD Diagnostics, Sparks, MD, USA), MGIT® (BD Diagnostics) and BacT/
ALERT® (bioMe’rieux SA, Marcy l’Etoile, France) have a shorter TAT, they are more expensive, 
require specialized laboratories and trained laboratory personnel [63].
Nucleic acid amplification molecular methods offer several advantages over the conventional 
culture-based methods which include rapid diagnosis and standardized testing.
In 2005 a meta-analysis of one of the two commercially line-probe assays (LiPAs) that were 
available then; the INNO-LiPA Rif.TB (Innogenetics, Ghent Belgium) [64] was conducted.
The INNO-LiPA Rif.TB (LiPA) test simultaneously detects MTBC and a mutation in the rpoB 
gene associated with RIF resistance. The test involves extraction of DNA from cultures or 
directly from clinical specimens, amplification of the RIF resistance-determining region of 
the rpoB gene using PCR, hybridization of the biotinylated PCR products with immobilized 
probes and determination of results by color-metric development [64].
The meta-analysis to evaluate the accuracy of LiPA for RIF resistance detection comprised of 
15 studies which comprised 11 studies that used culture isolates, 1 study that used clinical 
isolates and 3 studies that used both [64]. The sensitivity and specificity were greater than 95 
and 100% respectively in 12 of the 14 studies that used culture isolates in the LiPA test. In the 
4 studies that used clinical isolates in the LiPA test, sensitivity ranged between 80 and 100% 
whilst specificity was 100%. The authors concluded that although LiPA is a highly sensitive 
and specific test for detection of RIF resistance in culture isolates because of the lower sensi-
tivity when used directly on clinical specimens, more evidence is required before the test can 
be used to detect MDR TB among populations at risk in clinical practice [64].
In 2008 a meta-analysis of the second LiPA commercially available in the early 2000, the 
Genotype MTBDR (Hain Life Sciences, Gmbh, Nehren Germany) was performed [65]. The 
Genotype MTBDR (MTBDR) test detects the mutations in the rpoB and katG genes associated 
with RIF and isoniazid (INH) resistance respectively. The meta-analysis included 10 pub-
lished articles contributing 14 comparisons and 15 comparisons for detection of RIF and INH 
respectively. The pooled sensitivity and specificity for RIF resistance across all the subgroups 
was 91.1 and 98.7% respectively. The pooled specificity for detection of INH resistance was 
99.5%, but the sensitivity was variable and inconsistent, 84.3% (95% CI:76.6–89.8). Ling et al. 
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concluded that MTBDR assay also referred to as MTBDRsl Version 1 (now referred to simply 
as Hain version 1) has excellent accuracy for RIF resistance detection. Although specificity for 
detection of INH resistance was excellent, the sensitivity was modest and variable [65].
In 2008, following the two meta analyses to assess the diagnostic accuracy of LiPA and MTBDR 
assays, the WHO recommended the use of these LiPAs for MTBC and RIF resistance detection 
in sputum smear-positive specimens (direct testing) and in cultured isolates of MTBC (indi-
rect testing) [66]. Since then, newer versions of the two LPAs have been developed and a third 
one, Nipro NTM + MDRTB detection kit 2 (Tokyo, Japan) which detects MTBC, RIF and INH 
resistance has been introduced.
The FIND evaluated the Nipro and the Hain version 2 LPAs and compared them with Hain 
version 1 in 2015. The study reported that these three LPAs showed equivalence for detecting 
TB and resistance to RIF and INH [67].
An updated systematic review of the accuracy of the three LiPAs (Hain version 1, Hain ver-
sion 2 and Nipro) for detecting MTBC and resistance to RIF and INH was commissioned by 
the WHO in 2015. The review included 74 studies comprising 94 unique datasets of which 
83 datasets evaluated Hain version 1, 5 evaluated Hain version 2, and 6 evaluated the Nipro 
assay. Subsequently, the WHO in 2016, issued a Policy update on the use of molecular LPAs 
for the detection of resistance to INH and RIF [68]. The mutation probes used for detection 
of RIF resistance (rpoB), high level INH resistance (katG), and low-level isoniazid resistance 
(inhA) are the same for the three assays with the exception of the katG S315N mutation, which 
is included in the Nipro assay but not in Hain version 1 or version 2 [68].
Hain version 1 was developed to genotype resistance to FLQ via gryA, SLID resistance (SLID 
including KAN, AMK and CAP) via rrs and ethambutol (EMB) resistance via embB. Hain ver-
sion 2 also targets gyrA but includes assays for gyrB mutations that are also associated with 
FLQ resistance. Furthermore, the assay incorporates further SLID resistance genotypes via the 
eis promoter region. The embB resistance component is not used in the Hain version 2.0 [69].
Subsequent to the meta-analysis, the WHO recommended that the commercial molecular 
LiPAs may be used as the initial test instead of phenotypic culture-based DST to detect RIF 
and INH in persons (children and adults) with a sputum smear-positive specimen (direct 
testing) or a cultured isolate of MTBC (indirect testing). However, the accuracy of detecting 
resistance to RIF and INH differs leading to an overall reduced accuracy of MDR TB diagno-
sis. LiPAs are not recommended to replace conventional culture-based DST, which may still 
be necessary to determine resistance to other anti-TB agents and to monitor the emergence 
of additional drug resistance. Furthermore, when the LiPA result does not detect INH resis-
tance, conventional culture-based DST for INH may still be used to evaluate patients particu-
larly for populations with a high pre-test probability of resistance to INH [68].
2.7. TB skin test for diagnosis of latent TB infection
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to 
stimulation by Mycobacterium tuberculosis (MTB) antigens without evidence of clinically 
manifested active TB. LTBI will lead to active TB disease in approximately 5–10% of these 
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individuals during their lifetimes; [70], the risk is higher in younger children [71], the immu-
nocompromised or immunosuppressed [72, 73], and in people from countries with a high 
incidence of TB (≥40 cases per 100,000) [74].
Diagnosis of LTBI is important as those found positive may be initiated on prophylactic treat-
ment, thus preventing development of active TB and indirectly preventing transmission for 
those found to have disease and commenced on anti-TB treatment.
The TB Skin test (TST) is one of the oldest diagnostic tests developed in the 19th century but 
which is still being widely used [75]. The standard recommended test is the Mantoux test, which 
is administered by intradermal injection of a 0.1 mL of liquid containing 5 tuberculin units (TU) 
of purified protein derivative (PPD) or 2 TU PPD RT23 (these are considered equivalent) into the 
top layers of skin of the forearm. The test is read 48–72 h after the injection [76]. Although widely 
used the test has several limitations; a positive reaction may be observed in both latent and active 
TB infection, therefore, it is unreliable in differentiating whether the person is currently having 
TB or had been infected in the past or at carrier stage; false positive reactions may occur which 
could be attributed to infection with non-tuberculosis mycobacteria (NTM), previous Bacillus 
Calmete Guerin (BCG) vaccination [77], incorrect method of TST administration, incorrect inter-
pretation of reaction, incorrect bottle of antigen used; false negative reactions due to cutaneous 
anergy, recent TB infection (within 8–10 weeks of exposure), very old TB infection, very young 
age (less than 6 months old), recent live-virus vaccination (e.g., measles and smallpox), over-
whelming TB disease, some viral illnesses (e.g., measles and chicken pox) [78, 79]. Thus, a confir-
matory test such as sputum culture, is usually done to rule out an active TB infection.
HIV-infected patients may have a compromised ability to respond to the TST because of cutane-
ous anergy [80, 81]. Tuberculin skin testing assesses the ability to mount a delayed type hyper-
sensitivity (DTH) cell mediated immune response to PPD. Since in HIV infection, there is a 
gradual decrease in CD4+ T lymphocytes, as HIV disease progresses, the HIV-infected patients 
tend to have an impaired DTH response, which plausibly may cause a false negative TST result.
The TST, however can be used for differential diagnosis of TB from sarcoidosis, another granu-
lomatous disease with similarities to TB. Whilst TST has a high sensitivity for sarcoidosis, it has 
been reported to have a poor specificity for TB. In the general population, a negative TST is a 
specific test for sarcoidosis, in contrast, a positive TST in a sarcoidosis patient is a specific test for 
indicating TB. Thus a thorough TB workup should be done in a sarcoidosis suspect patient [82].
In 2015, the WHO strongly recommended the TST for diagnosis of latent TB in high- and 
upper medium-income countries with low TB burden (estimated TB incidence less than 100 
per 100,000), in the HIV-infected patients, adult and child contacts of pulmonary TB cases, 
patients initiating anti-tumor necrosis factor treatment, patients receiving dialysis, patients 
preparing for organ or haematologic transplantation, and patients with silicosis [83].
2.8. Interferon gamma release assays for diagnosis of latent TB infection
The Interferon gamma release assays (IGRAs) measure, using an enzyme-linked immunosor-
bent assay (ELISA) or an enzyme-linked immunospot (ELISPOT) the release of Interferon-γ 
(IFN-γ) from T lymphocytes following stimulation of the cells with MTB-specific antigens 
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There are two commercially available IGRAs: the QuantiFERON® TB Gold (Cellestis Ltd., 
Carnegie, Victoria, Australia) and the T-SPOT® TB IGRAs (Oxford Immunotec, Oxford, 
United Kingdom).
In the first-generation QuantiFERON-TB assay, whole-blood is stimulated with PPD and ELISA 
used to measure the concentration of IFN-γ released by the T lymphocytes [84]. The enhanced 
form of the assay, the QuantiFERON-TB Gold uses the MTB-specific antigens: early-secreted anti-
genic target 6-kDa protein (ESAT-6) and culture filtrate protein 10 (CFP-10) instead of PPD [84]. 
In the newer version of the assay, QuantiFERON-TB Gold In-Tube, heparinized venous blood is 
added to the tube coated with the MTB-specific antigens; ESAT-6, CFP-10, and TB 7.7 [84].
In the T SPOT-TB assay, peripheral blood mononuclear cells are stimulated with ESAT6 and 
CFP10 and the released IFN-γ detected using an ELISPOT assay [85].
These assays are not routinely used in Resource-Limited Settings (RLS) because they are 
expensive, require expensive equipment and advanced technical expertise.
In 2015, the WHO recommended the use of IGRAs for the diagnosis and treatment of LTBI 
in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating 
anti-tumor necrosis factor treatment, patients receiving dialysis, patients preparing for organ 
or haematologic transplantation, and patients with silicosis, prisoners, healthcare workers, 
immigrants from high TB burden countries, homeless persons and illicit drug users and in 
high-income and upper middle-income countries with estimated TB incidence less than 100 
per 100,000 [76].
The advantages of the IGRAs include only a single patient visit to conduct the TB test, the 
results can be available within 24 h, and prior BCG vaccination does not cause a false positive 
result. The disadvantages include; the requirement to process the collected blood specimen 
fairly rapidly (within 8–16 h following blood collection), laboratory facilities are required, and 
the test is only for latent TB. Furthermore, the IGRAs may not be as accurate in people who 
are HIV-infected [72].
2.9. Chest radiography
Chest X-rays (CXRs) are not considered as specific diagnostic tests for TB. However, because 
of the low sensitivity of SSM in TB diagnosis of HIV-infected patients, in 2007, the WHO 
recommended use of CXRs in HIV-infected patients who are SSM negative [86]. The chest 
X-ray plays an important role in the diagnosis of TB among people living with HIV and can 
also be an important entry point to diagnosing non-tubercular chest diseases, which are com-
mon among people living with HIV. CXR presentations of TB in HIV-infected patients are 
now well characterized and CXR play a significant role in shortening delays in diagnosis and 
should be performed early in the course of investigation of a tuberculosis suspect [86]. Indeed 
in a randomized controlled trial of Xpert MTB/RIF versus SSM conducted in four countries in 
southern Africa, the majority of the HIV-infected patients in the SSM arm who were smear-
negative were commenced on anti-TB treatment based on radiological findings with or with-
out clinical symptoms, whilst awaiting results from culture [33].
Tuberculosis82
In 2016, the WHO published a factsheet and issued new recommendations and guidance 
on the use of chest radiography for TB detection in National TB care [87, 88]. CXR may 
play an essential role as a sensitive tool in diagnosis of childhood pulmonary and extra-
pulmonary TB and in excluding active TB prior to treatment of LTBI. Since CXR on their 
own cannot establish a TB definite diagnosis, in an algorithm of TB screening that involves 
TB symptoms screening, CXR can also be used as a sensitive tool for screening for active 
TB, this may improve the pre-test probability of the subsequent diagnostic test and lead 
to a reduction in the number of people who need to undergo further diagnostic evalua-
tion [89]. CXR is also used in TB prevalence surveys as it is considered the most sensitive 
screening tool for identifying those survey participants with a high probability of having 
TB. An abnormal CXR and or positive symptom screen is then followed by bacteriological 
confirmation [90].
The limitations in the wider use of chest X-rays, include non-availability at peripheral health 
facilities and the difficulty of interpreting results, even by trained physicians.
3. Conclusion
The upsurge of one the oldest known infectious diseases, TB, coupled with the HIV/AIDS 
pandemic, emergence of MDR TB and XDR TB has led to unprecedented efforts in develop-
ing new TB diagnostic tools which can detect TB and resistance to first line and second line 
anti-TB drugs more rapidly. Whilst SSM remains the most used tool in diagnosis of pulmo-
nary TB in the majority of countries that harbor the highest burden of TB, new molecular-
based amplification techniques, LiPAs which provide results faster have been developed. 
However, these tests are not available to the majority of the countries with the highest TB 
burden mainly because of costs, requirement of specialized laboratory and trained personnel 
with the exception of the Xpert MTB/RIF assay which can be performed by any healthcare 
giver after minimum training.
The urgent need for development of a true POC TB test with operational simplicity similar to 
the rapid HIV antibody POC test, which is accurate, easy to use, does not require a laboratory, 
laboratory trained personnel, nor electricity and is affordable cannot be overemphasized if the 
Global Strategy and Targets for Tuberculosis Prevention, Care and Control goal of eliminating 
TB as a public health threat by 2030 is to be achieved.
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